Solid Biosciences Inc (SLDB)

$3.27 +0.02 (0.62%)
Market Cap 129.85M
Revenue (ttm) 0.00
Net Income (ttm) -96.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 495,100
Avg Vol 402,702
Day's Range N/A - N/A
Shares Out 39.96M
Stochastic %K 14%
Beta 2.05
Analysts Strong Sell
Price Target $16.82

Latest News on SLDB

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 15, 2025, 4:05 PM EST - 3 days ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 10 days ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Jan 7, 2025, 4:15 PM EST - 11 days ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 26 days ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Dec 13, 2024, 1:52 PM EST - 5 weeks ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Solid Biosciences to Participate at Upcoming Investor Conferences

Nov 26, 2024, 8:00 AM EST - 7 weeks ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 2 months ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 2 months ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2024, 4:15 PM EDT - 3 months ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:00 AM EDT - 4 months ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:08 PM EDT - 5 months ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2024, 4:19 PM EDT - 7 months ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 15, 2024, 7:52 AM EDT - 8 months ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10, 2024, 7:32 PM EDT - 10 months ago

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Apr 1, 2024, 7:45 AM EDT - 10 months ago

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Mar 13, 2024, 7:44 AM EDT - 11 months ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 16, 2024, 11:01 PM EST - 1 year ago

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Jan 16, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Announces $109 Million Private Placement

Jan 8, 2024, 7:09 AM EST - 1 year ago

Solid Biosciences Announces $109 Million Private Placement

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 1 year ago

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Nov 8, 2023, 4:17 PM EST - 1 year ago

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Oct 2, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Aug 14, 2023, 4:17 PM EDT - 1 year ago

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

May 22, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

May 16, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

Solid Biosciences Provides First Quarter Business Update and Financial Results

May 11, 2023, 7:30 AM EDT - 1 year ago

Solid Biosciences Provides First Quarter Business Update and Financial Results

Solid Biosciences to Present at JMP Securities Life Sciences Conference

May 8, 2023, 4:05 PM EDT - 1 year ago

Solid Biosciences to Present at JMP Securities Life Sciences Conference

Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 21, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

Apr 13, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Mar 23, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

Mar 21, 2023, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

Solid Biosciences to Present at Barclays Global Healthcare Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at Barclays Global Healthcare Conference

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

Feb 8, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA's Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

Jan 26, 2023, 8:00 AM EST - 2 years ago

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA's Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Jan 11, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

Jan 9, 2023, 4:26 PM EST - 2 years ago

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer

Jan 9, 2023, 8:01 AM EST - 2 years ago

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 9, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Dec 5, 2022, 7:30 AM EST - 2 years ago

Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio

Dec 1, 2022, 4:15 PM EST - 2 years ago

Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio

SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB

Nov 12, 2022, 10:30 AM EST - 2 years ago

SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB

Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results

Nov 10, 2022, 7:34 AM EST - 2 years ago

Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results

Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

Oct 17, 2022, 8:00 AM EDT - 2 years ago

Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function

Oct 13, 2022, 8:00 AM EDT - 2 years ago

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Sep 30, 2022, 7:00 AM EDT - 2 years ago

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results

Aug 11, 2022, 7:53 AM EDT - 2 years ago

Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality

Jun 2, 2022, 8:30 AM EDT - 2 years ago

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality

Solid Biosciences Inc. (SLDB) CEO Ilan Ganot on Q1 2022 Results - Earnings Call Transcript

Apr 30, 2022, 5:25 PM EDT - 2 years ago

Solid Biosciences Inc. (SLDB) CEO Ilan Ganot on Q1 2022 Results - Earnings Call Transcript